Resource data sheet
Prev.
Please review the QC test results indicated by check icon below as well as clone information before placing your order.

pENTER-EGFR Del19

Gateway(R) entry vector of human epidermal growth factor receptor (EGFR), EGFR-activating mutation.

Catalog number RDB15489
Resource name pENTER-EGFR Del19
Clone info. Gateway(R) entry vector of human epidermal growth factor receptor (EGFR) mutant, deletion in exon 19, EGFR-activating mutation.
Comment cDNA was obtained from HCC-827 cells. Expression was confirmed by the depositor with western blotting after cloned into pLenti6.3 vector (by LR clonase II reaction). This clone contains a cDNA fragment corresponding to the 258nt to 3890nt of NM_005228.4. Known differences (at least) : C to T substitution at 731nt (N, synonym) ; 15nt (del19) deletion at 2493 to 2507nt ; G to A substitution at 2618nt (Q, synonym).
Vector backbone pENTR (plasmid)
Size of vector backbone 2.6 kb
Selectable markers Kan^r
Gene/insert name human EGFR cDNA
Depositor|Developer Katayama, Ryohei |
Other clones in our bank

External Database
human EGFR

          Reference sequence
            
           

          Distribution information

          Please check terms and conditions set forth by the depositor, which are specified in the RIKEN BRC Catalog and/or Web Catalog.
          Terms and conditions for distribution In publishing the research results obtained by use of the BIOLOGICAL RESOURCE, a citation of literature designated by the DEPOSITOR is requested. (Uchibori, K et al. Nat. Commun. 8: 14768, 2017)
          Ordering Please visit Information of Request for Distribution.[link] 
          Order form 
          [Credit Card Payment]  [Bank Transfer Payment]
          Material Transfer Agreement (MTA for use for not-for-profit academic purpose) [Word]
          Remarks
          Gateway® Entry clone. Please refer Life Technologies Corporation signs license agreement with RIKEN BRC.
          提供案内 (日本国内) [open/close]

          提供条件 利用者は、研究成果の公表にあたって寄託者の指定する文献を引用する(Uchibori, K et al. Nat. Commun. 8: 14768, 2017)。
          提供依頼 手続きの詳細は、「提供申込みについて[link]」をご覧ください。
          提供依頼書 [Word]
          提供同意書 (MTA、非営利機関による非営利学術研究用)[Word]
          備考
          Gateway®テクノロジーを用いたエントリークローンです。「Gateway®テクノロジーを用いたクローンの提供と寄託のご案内」をご覧ください。

          Catalog # Resource name Shipping form Fee (non-profit org.)
          RDB15489 pENTER-EGFR Del19 DNA solution

          Please review the QC test results indicated by check icon below as well as clone information before placing your order.

          How to cite this biological resource

          Materials & Methods section:

          The pENTER-EGFR Del19 was provided by the RIKEN BRC through the National BioResource Project of the MEXT, Japan (cat. RDB15489).

          Reference section:

          Uchibori, K., Inase, N., Araki, M., Kamada, M., Sato, S., Okuno, Y., Fujita, N., Katayama, R., Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer. Nat. Commun. 8: 14768 (2017). PMID 28287083.

          Further references such as user reports and related articles (go to bottom)


          References and tips

          Featured content


          QC test results

          RIKEN BRC has sequenced portions of this material for quality test.
          Please review the QC test results indicated by check icon as well as clone information before placing your order.

          Test sheet RDB15489_A7K8p1-2.pdf check

          Nucleotide sequence of a portion of this resource (if available).

          Primer: rrnBT1ter_F2 (Pr0531)
          Region: attL1, insert 5'
          Sequence file: RDB15489_A7K8d.seq check
          >D04925A2_A7K8_2_rrnBT1ter_F2_B04_04_ABI24.ab1
              1 NNNNNNNNNN NNNNNNNNNN NNNCCTTTCG TTTNNTTTGA NGCCTGGCAG TTCCCTACTC
             61 TCGCGTTAAC GCTAGCATGG ATGTTTTCCC AGTCACGACG TTGTAAAACG ACGGCCAGTC
            121 TTAAGCTCGG GCCCCAAATA ATGATTTTAT TTTGACTGAT AGTGACCTGT TCGTTGCAAC
            181 AAATTGATGA GCAATGCTTT TTTATAATGC CAACTTTGTA CAAAAAAGCA GGCTCCGCGG
            241 CCGCCCCCTT CACCATGCGA CCCTCCGGGA CGGCCGGGGC AGCGCTCCTG GCGCTGCTGG
            301 CTGCGCTCTG CCCGGCGAGT CGGGCTCTGG AGGAAAAGAA AGTTTGCCAA GGCACGAGTA
            361 ACAAGCTCAC GCAGTTGGGC ACTTTTGAAG ATCATTTTCT CAGCCTCCAG AGGATGTTCA
            421 ATAACTGTGA GGTGGTCCTT GGGAATTTGG AAATTACCTA TGTGCAGAGG AATTATGATC
            481 TTTCCTTCTT AAAGACCATC CAGGAGGTGG CTGGTTATGT CCTCATTGCC CTCAACACAG
            541 TGGAGCGAAT TCCTTTGGAA AACCTGCAGA TCATCAGAGG AAATATGTAC TACGAAAATT
            601 CCTATGCCTT AGCAGTCTTA TCTAACTATG ATGCAAATAA AACCGGACTG AAGGAGCTGC
            661 CCATGAGAAA TTTACAGGAA ATCCTGCATG GCGCCGTGCG GTTCAGCAAC AACCCTGCCC
            721 TGTGCAATGT GGAGAGCATC CAGTGGCGGG ACATAGTCAG CAGTGACTTT CTCAGCAACA
            781 TGTCGATGGA CTTCCNGANN CACCTNNGCA GCTGCCAAAA GTGTGATCCA AGCTGTCCCA
            841 ATGGGANCTG CTGGGGTGCA NGANANGANA NNTGCCAGAA ACTGANNAAA ATCATCTGNG
            901 CCCANCAGNG CTCCNGGNNC TGCCGNGGCA NNNCCCCCNA NNNNNNGCTN NCNNNACCAG
            961 NGNNCTGCNN NNNGCNNNNN NCCCNNNGGN NANCNNNNGN CNNNNNNNNN CNNNNAATNN
          1021 CNNNNNNNAN NNNNNNNNN
          //
          Primer: pDONR_R (Pr0071)
          Region: attL2, insert 3'
          Sequence file: RDB15489_A7K8e.seq check
          >D04925A2_A7K8_2_pDONR_R_B08_05_ABI24.ab1
              1 NNNNNNNNNN NGNNNNNCNN TGNNNNTGTA NTACGACTCN CTATAGGGGA NATCAGCTGG
             61 ATGGCAAATA ATGATTTTAT TTTGACTGAT AGTGACCTGT TCGTTGCAAC AAATTGATAA
            121 GCAATGCTTT CTTATAATGC CAACTTTGTA CAAGAAAGCT GGGTCGGCGC GCCCACCCTT
            181 TCATGCTCCA ATAAATTCAC TGCTTTGTGG CGCGACCCTT AGGTATTCTG CATTTTCAGC
            241 TGTGGAGCCC TTAAAGATGC CATTTGGCTT GGCTTCCTTG GGAAAGAAGT CCTGCTGGTA
            301 GTCAGGGTTG TCCAGGCTAA TTTGGTGGCT GCCTTTCTGG GCCCAGTGGG CAGGGCTGTC
            361 GAATGTGCTG TTGACACAGG TGGGCTGGAC AGTGTTGAGA TACTCGGGGT TGCCCACTGC
            421 AGTGCTGTGG GGGTCCTGGT AGTGTGGGTC TCTGCTGGGC GCGGGGTTCA GAGGCTGATT
            481 GTGATAGACA GGATTCTGCA CAGAGCCAGC GGGCCTTTTG GGAACGGACT GGTTTATGTA
            541 TTCAGGCACT GGGAGGAAGG TGTCGTCTAT GCTGTCCTCA GTCAAGGCGC CTGTGGGGTC
            601 TGAGCTGTAT CGCTGCAAGA AGCTGTCTTC CTTGATGGGA CAGCTTTGCA GCCCATTTCT
            661 ATCAATGCAA GCCACGGTGG AATTGTTGCT GGTTGCACTC AGAGAGCTCA NGANGGGAGT
            721 CCGTGACGTG GANGGGCTGC TGAAGAAGCC CTGCTGTGGG ANGANGTACT CGTCGGCATC
            781 CACCACGTCG TCCATGTCTT CTTCATCCAT CANGGCACGG TANAAGTTGG ANTCTGTANG
            841 ANTNNNCAAA TGCATTCTTT CNTCCCCCNN AANGACAAGG NANCGCNGGG GGNNCTCGGN
            901 NCATTTNNNA NAANNCNATG NTCNACTCNN NGNANNTTTG GNNNANTATC NNCNNNNNNN
          961 NNN
          //
          Primer: EGFR-F5 (Pr0313)
          Region: insert mid (del19)
          Sequence file: RDB15489_A7K8f.seq check
          >D04925A2_A7K8_2_EGFR-F5_B09_06_ABI24.ab1
              1 NNNNNNNNNN NNNNNNNNNN NNGGNNGGTG GGGGCCCTCC TCTTGCTGCT GGTGGTGGCC
             61 CTGGGGNTCG GCCTCTTCAT GCGAAGGCGC CACATCGTTC GGAAGCGCAC GCTGCGGAGG
            121 CTGCTGCAGG AGAGGGAGCT TGTGGAGCCT CTTACACCCA GTGGAGAAGC TCCCAACCAA
            181 GCTCTCTTGA GGATCTTGAA GGAAACTGAA TTCAAAAAGA TCAAAGTGCT GGGCTCCGGT
            241 GCGTTCGGCA CGGTGTATAA GGGACTCTGG ATCCCAGAAG GTGAGAAAGT TAAAATTCCC
            301 GTCGCTATCA AGACATCTCC GAAAGCCAAC AAGGAAATCC TCGATGAAGC CTACGTGATG
            361 GCCAGCGTGG ACAACCCCCA CGTGTGCCGC CTGCTGGGCA TCTGCCTCAC CTCCACCGTG
            421 CAACTCATCA CGCAGCTCAT GCCCTTCGGC TGCCTCCTGG ACTATGTCCG GGAACACAAA
            481 GACAATATTG GCTCCCAGTA CCTGCTCAAC TGGTGTGTGC AGATCGCAAA GGGCATGAAC
            541 TACTTGGAGG ACCGTCGCTT GGTGCACCGC GACCTGGCAG CCAGGAACGT ACTGGTGAAA
            601 ACACCGCAGC ATGTCAAGAT CACAGATTTT GGGCTGGCCA AACTGCTGGG TGCGGAAGAG
            661 AAAGAATACC ATGCAGAAGG AGGCAAAGTG CCTATCAAGT GGATGGCATT GGAATCAATT
            721 TTACACAGAA TCTATACCCA CCAGAGTGAT GTCTGGAGCT ACGGGGTGAN CGTTTGGGAG
            781 TTGANGACCT TTGGATCCNA GCCATATGAC GGANTCCCTG CCAGCGAGAT CTCCTCCATC
            841 CTGGANAAAG GANAANGCCT CCCTCANCCA CCCATATGTA CCATCNATGT CTACATGATC
            901 ATGGNCAAGN GCNNGNNGAN AGANNNANAN AGTCGNCCNA ANTNNCNNNA GTNNNTNATC
          961 GNANTTCNNC NAAANNNNCN NNNNNCNNCN NNNNNNNNCN NNNNNNNNN
          //

          Please visit Sequencing and PCR primers for primer information.


          References

          Original, user report and related articles

          original Uchibori, K., Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer. Nat. Commun. 8: 14768 (2017). PMID 28287083.

          2023.05.01

          GNP_filter3_RDBDEP_html_230501.pl